SB-743971 IN PATIENTS WITH NON-HODGKINS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项在接受标准治疗后进展或复发的霍奇金或非霍奇金淋巴瘤成人患者中开展的SB-743921多中心、国际I-II期、开放标签、非随机、剂量探索研究。 研究的I期部分将包括在标准治疗中进展或复发的霍奇金病或NHL患者，而II期研究将限于在标准治疗中进展或复发的具有可测量疾病的NHL患者。SB-743921将在28天周期的第1天和第15天单次静脉输注给药。研究的第1期和第2期均包括筛选期、治疗期和治疗后阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, international Phase I-II, open-label, non-randomized, dose finding study of SB-743921 in adult patients with Hodgkin¿s or Non-Hodgkin¿s lymphoma who have progressed on standard therapy or who have relapsed. The Phase I portion of the study will include patients with either Hodgkin¿s Disease or NHL who have progressed on standard therapy or relapsed, while the Phase II study will be limited to NHL patients with measurable disease who have progressed on standard therapy or relapsed. SB-743921 will be administered as a single intravenous infusion on Days 1 and day 15 of a 28-day cycle. Both Phases 1 and 2 of the study will consist of a screening period, treatment period, and a post-treatment period.